Introduction
Since the 1930s, it has been known that rare forms of Alzheimer's disease (AD) are fully genetically determined because they present an autosomal dominant mode of inheritance. As with all such genetic diseases, it was not until the 1980s that systematic linkage approaches for characterizing the causative genes were developed. In this context, three genes (APP, PSEN1 and PSEN2, coding respectively for amyloid precursor protein, presenilin-1 and presenilin-2) were found to be responsible for early onset, dominantly inherited forms of AD [1] . These rare mutations causing autosomal dominant forms of the disease gave rise to the amyloid cascade hypothesis, which radically changed our understanding of AD.
The vast majority of cases of AD are late-onset 'sporadic' forms, with no obvious familial aggregation. However, AD appears to be one of the human multifactorial diseases with the highest level of heritability ($70%) [2] -a similar level to that observed for schizophrenia ($80%), and well above those found for diabetes ($40%) [3] and Parkinson's disease ($30%) [4] .
In 1993, it was reported that the e4 allele of the apolipoprotein E (APOE) gene was associated with the risk of developing AD [5] . Since then, this association has been detected in almost all ethnic groups -with the notable exception of some African populations [6, 7] . Because of the discovery of APOE and the strength of the genetic component in AD, our knowledge of the genetics of this disease was expected to increase rapidly, but it was not until the late 2000s that other genetic risk factors were characterized thanks to the advent of high-throughput genomic approaches. In particular, genome-wide association studies (GWASs) enabled researchers to study tens of thousands of individuals and (after imputation) millions of genetic variations. In 2009, the publication of the results of the first two large-scale GWASs of AD constituted a milestone in this field, with the discovery of three new genetic risk factors: CLU, CR1 and PICALM [8, 9] .
High-throughput genomic approaches are shaping our understanding of the genetics of Alzheimer's disease Since the publication of these seminal studies, the AD GWAS field has moved in several complementary directions and has led to the discovery of additional genetic risk factors of AD. Firstly, the development of large international GWAS consortia (e.g. the International Genomics of Alzheimer's Project (IGAP)) has greatly increased the scale of the discovery phase (e.g. n = 17 008 AD cases and 37 154 controls analyzed in the first IGAP study) and thus its statistical power [10] . To note, the definition of around 40 000 proxy-AD cases in the UK biobank (based on selfreports of a family history of Alzheimer's dementia) has increased the statistical power of the discovery phase of recent studies [11 ,12,13 ] . However, the relevance of this 'virtual diagnosis' can be criticized, and nevertheless constitutes a major limitation. Secondly, ever broader reference panels are being used for imputation, with 1092 individuals initially in the 1000 Genomes Project in 2012, 32 470 individuals in the Haplotype Reference Consortium and (in the near future) 62 784 individuals in the Trans-Omics for Precision Medicine panel [14] . Better reference panel has expanded the number of variants analyzed and increased the imputation quality, especially for rare variants. Thirdly, the use of relevant endophenotypes can allow to detect novel signals [15 ] . Lastly, the development of new genotyping tools has made it possible to probe non-synonymous, rare variants [16 ] . In addition, a marked fall in the cost of next-generation sequencing has enabled the latter's application to multifactorial diseases for which the detection of signals of interest, that is, rare variants, requires a large number of samples. These sequencing approaches have shown that rare variants in TREM2, SORL1 and ABCA7 for example are major genetic risk factors for AD [17] [18] [19] [20] [21] . Recently, the Alzheimer Disease Sequencing Project, the largest sequencing effort in AD to date, published its first whole-exome sequencing results for 5740 cases of lateonset AD and 5096 cognitively normal controls [22] . Rare (and common) variants in several additional genes were found to be potentially associated with the AD risk [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] .
Hence, over the last ten years, more than 40 AD-associated genes/loci have been identified by GWASs and sequencing projects (Tables 1 and 2) [43 ] .
Sequencing projects and GWASs do not represent the absolute truth: biases and limitations
Even though high-throughput genomic approaches are very powerful means of detecting even weak associations, it is important to bear several important aspects in mind. In all cases, the quality of the research results depends on the quality of the populations studied, that is, the reliability of the diagnosis of AD, and the ability to limit classical epidemiologic biases. In view of the large number of tests, high-throughput approaches must strike a balance between the risk of observing apparently significant results by chance and the risk of rejecting biologically valid hypotheses on purely statistical grounds. Unfortunately, the solution to this problem has not yet been found. Correction for multiple testing is common to define the significance threshold, and is mainly based on the number of theoretically independent tests performed, for example, p < 5 Â 10 À8 for single variant analyses or p < 2 Â 10 À6 for gene-based analyses. These are arbitrary significance thresholds for determining whether or not a signal is valid, and they do not tell the researcher whether the observed signal is real. Nevertheless, a genuine association signal with the risk of developing AD should increase as the size of the study population grows -as long as the populations are similar with regard to the ethnic origins, age, diagnostic criteria, and so on. By way of an example, the signal for BIN1 was 1.59 Â 10 À11 (OR:1.15 [1.11-1.20] ) in the initial study [44] and 2.1 Â 10 À44 (OR:1.20 [1.17-1.23]) in the latest study [45 ] -a clear indication that the signal is solid. In contrast, the CD33 gene was initially reported to be associated with the AD risk in two independent GWASs published in 2008 [46] and in 2011 [47, 48] but not in some of the larger GWASs published from 2013 to 2019 [10, 45 ] ; this raises questions about CD33's relevance. However, when the signal fluctuates around the genome-wide significance threshold of 5 Â 10 À8 and gives rise to discrepancies between studies, one cannot rule out for example interactions with hidden heterogeneity in the studies such as as-yet unknown interaction between genetic or environmental factors. To note, fluctuation is particularly problematic in studies of rare variants; random fluctuations in rare variant frequencies in a given sample (controls and/or cases) can mask or artificially increase a variant's association with the AD risk.
Regardless of the variant frequency, the signal should never be detected in just one study (but homogeneous between different equivalent populations); its observation in several independent GWASs indicates that the result was not driven by unknown biases in the initial study population. This latter point can nevertheless be problematic; the IGAP's summary statistics are publicly available since 2013 and most of the subsequent GWASs in AD are not necessarily independent of the IGAP results.
What meaning can we give to GWAS and sequencing data?
One of the main objectives of basic genetic research on AD is to discover and characterize the underlying pathophysiological pathways and thus gain a better biological understanding of the disease. This work is based on the postulate whereby non-random groupings of genetic determinants constitute clues as to the nature of the disease pathway involved.
In silico gene set enrichment approaches have been used to characterize potential pathways of interest. These analyses have confirmed the involvement of the expected pathways (such as APP and Tau processing) but have also highlighted the regulation of endocytosis, cholesterol transport, protein ubiquitination, and innate immunity [13 ,45 ,49] . However, it is important to bear in mind that gene set enrichment approaches have limitations and notably may not be detailed enough to accurately track the pathogenesis of AD. In view of this concern, researchers have developed biological approaches (referred to as 'post-GWAS analyses') for assessing the potential roles of genetic factors in APP/Ab metabolism, Tau toxicity and other potential pathophysiological processes [50] [51] [52] [53] . For instance, many different genes appear to be involved in APP metabolism, Ab peptide clearance, and Ab toxicity [43 ] . In addition, there is high-quality evidence to suggest that BIN1 is involved in Tau pathology [54] . The combination of post-GWAS analyses with bibliographical data may reveal additional levels of complexity and thus generate various non-exclusive hypotheses, as proposed Table 1 Locus for which the association with AD risk is validated by the most recent GWAS and/or sequencing projects in the cell phase or genetically driven synaptic failure hypotheses [43 ,55 ] .
Another means of studying the genetic factors in AD is to better characterize functional variants. In some cases, a variant's impact on biological function is obvious (e.g. loss-of-function frameshift mutations in SORL1 and ABCA7). These genetic observations obviously will facilitate the development of relevant models. For instance, the genetic data have unambiguously revealed the importance of a specific cell type -the microglia -in the development of AD [16 ] . Reports of non-synonymous variants in TREM2, associated with AD risk led to obviously develop relevant hypothesis-driven studies in microglia and TREM2 is currently the most studied genetic risk factor in the context of the microgliadependent pathophysiological process in AD. TREM2 has been proposed to be protective in such a context since the AD-associated mutations (R47H, R62H) likely impair its physiological functions at two levels: (i) phagocytosis and clearance of Ab peptides and (ii) compaction of amyloid plaques and barrier formation [56, 57] .
It is important to keep in mind that, most of the GWAS signals are located in noncoding (and thus potentially regulatory) regions of the genome. However, it is possible to combine for example expression quantitative trait loci, active enhancers and/or gene expression (and so on) in different cell types and pathological tissues to determine functional variants and pathways in which the genes are potentially involved. A recent publication even suggested that the functional variants responsible for GWAS signals in many genes mainly drive gene expression in myeloid cells (and thus potentially in microglia) [58 ] . It is necessary to bear in mind that this was a hypothesis-driven study based on a human myeloid cell data repository and for obvious reasons, the absence of equivalent large datasets for human neurons and other brain cell types precludes similar analyses in these cell types [59 ] . However, it has been also suggested that numerous AD risk variants may be located in microglial-specific enhancers, strongly supporting again the importance of microglia in AD [60] .
What is the future for genetic analyses of Alzheimer's disease?
As mentioned above, our knowledge of the genetic component of AD has been greatly enhanced over the last 10 years. This knowledge has already changed the way the research community thinks about the AD processnotably by highlighting the potentially major role of microglia. However, the knowledge is far from complete; as is the case for other aging-related multifactorial diseases, major efforts to exhaustively characterize genetic factors in AD are still needed. This will probably require the implementation of several complementary strategies.
Firstly, larger GWASs of Caucasian and other ethnic groups are now underway or being planned. The European Alzheimer DNA Biobank project has just been launched; with approximately 38 000 AD cases and 60 000 controls in the discovery phase, it will be the world's largest GWAS. In the USA, large studies of African-American and Caribbean populations are being developed by the Alzheimer's Disease Genetics Consortium [61, 62] . Furthermore, reports from large GWASs in Asian populations are expected. Lastly, initiatives (albeit at a lower level) are also being taken in South America and Africa. These studies will leverage the most recent imputation panels, and are likely to highlight new genetic risk factors of AD (whether specific or not for various ethnic groups) and prompt the development of in-depth approaches for mapping functional variants as already performed in other multifactorial diseases [63] .
Secondly, large sequencing projects are underway in various ethnic groups [22 ,26,36] . Since the imputation quality is low for very rare variants, these sequencing approaches complement the GWASs results [22 ,23-42] .
It is important to bear in mind that this type of study is very sensitive to the available statistical power; most of the studies described to date were probably underpowered, resulting in the publication of false positives. However, this problem should rapidly disappear as lower sequencing costs enable the assessment of ever larger populations. Another direct consequence of the drop in cost will be a shift from whole-exome sequencing to whole-genome sequencing; given that the exome accounts for only 3% of the genome, this move will broaden the analysis of rare variants. New sequencing technologies (e.g. those based on long reads) should enable analyses of structural variants in a more efficient way that currently possible.
Thirdly, the diagnostic criteria for AD and related syndromes will become refined -notably through the increasing use of biomarkers [64, 65 ] . Although it is difficult to predict how this trend will impact studies of AD genetics, it is already clear that there will be a gap between today's case-control studies and those implemented in the future. Genetic analyses will probably be broadened to other, better diagnosed neurodegenerative diseases, and will potentially be able to define disease-specific genes and pathways or, on the contrary, common genes and pathways. This trend in diagnosis is also likely to prompt the redefinition of most of today's polygenic risk scores results and thus make them more relevant [66, 67] .
Following on from the characterization of missing genetic risk factors for AD, post-genomic studies will be required to give meaning to this data. As mentioned above, this is the most important challenge in studies of the pathophysiological processes in AD. One of the main temptations is to position newly identified genes in processes that are already thought to be involved in AD: Although this may well be the case, this prompts a move from a hypothesis-free approach (e.g. GWAS) to a hypothesisdriven approach. However, a main challenge will be to develop read-outs, more or less independently of our current knowledge, by developing new models. In fact, this type of holistic approach is already developed by making available "omics" databases in the brain, potentially including single-cell sequencing and atlases for all cell types [68 ,69 ,70 ] . These efforts are clearly needed for the most comprehensive, least biased vision of AD.
In any case, the combination of these strategies will either independently confirm known mechanisms or highlight new, unexpected processes.
Conclusion
Thanks to high-throughput genomic approaches, our knowledge of the genetics of AD has progressed significantly over the last 10 years. However, much work remains to be done to characterize the missing genetic factors and to separate the wheat from the chaff when considering published loci. Again, it is important to bear in mind that some published loci are probably false positives. Furthermore, the real objective of this research is to give biological meaning to genetic information, rather than to draw up a list of loci. This challenge is still in its early stages, and will require more and more effort. In this respect, purely reductionist approaches will not be able to capture the complexity induced by the growing number of genes/loci; only approaches that take account of this complexity are likely to be able to determine which pathophysiological processes are involved. Characterizing the missing AD genetic factors and developing post-GWAS approaches to understanding the factors' pathophysiological roles are probably among most promising and exciting areas of research in AD. Ultimately, this should lead to the development of personalized treatments that match the individual patient's genetic profile.
A major GWAS report clearly demonstrating that microglia is a major actor of the AD pathology. The three genes characterized in this study are mainly (or almost only) expressed in this type of cells and participate to the same Protein-protein interaction network than TREM2. 
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